Autopsy report · NCT04361851

Study of Dara-Pembro for Multiple Myeloma Patients

“Low enrollment due to competing studies”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

Pembrolizumab

Participants

0

Trials that died the same way

• Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
  “Low study participant enrollment.” (84% match in meaning)
• Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers
  “Low enrollment of qualified subjects” (79% match in meaning)
• LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
  “Low enrollment” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.